2-Aminopropane-1,2,3-tricarboxylic acid: Synthesis and co-crystallization with the class A β-lactamase BS3 of Bacillus licheniformis

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 13, 2008, Pages 3764-3768

  Beck, Joséphine ^a   Sauvage, Eric ^b   Charlier, Paulette ^b   Marchand Brynaert, Jacqueline ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Lactamase inhibitors; 2 Aminopropane 1,2,3 tricarboxylic acid; Aminocitrate BS3 complex; Glycine bis alkylation; X ray diffraction analysis

Indexed keywords

2 AMINOPROPANE 1,2,3 TRICARBOXYLIC ACID; BETA LACTAMASE; BETA LACTAMASE INHIBITOR;

ARTICLE; BACILLUS LICHENIFORMIS; COLUMN CHROMATOGRAPHY; DRUG INHIBITION; DRUG STRUCTURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; X RAY DIFFRACTION;

ASPARTIC ACID; BACILLUS; BACTERIAL PROTEINS; BETA-LACTAMASES; BINDING SITES; CATIONS; CHEMISTRY, PHARMACEUTICAL; CITRIC ACID; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ISOCITRATES; MODELS, CHEMICAL; MOLECULAR CONFORMATION; OXYGEN; TRICARBOXYLIC ACIDS; X-RAY DIFFRACTION;

BACILLUS LICHENIFORMIS;

EID: 44949106232     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.045     Document Type: Article

References (38)

1. Fisher J.F., Meroueh S.O., and Mobashery S. Chem. Rev. 105 (2005) 395
2. Sandanayaka V.P., and Prashad A.S. Curr. Med. Chem. 9 (2002) 1145
3. Fonze E., Vanhove M., Dive G., Sauvage E., Frere J.-M., and Charlier P. Biochemistry 41 (2002) 1877
4. Durnow A., and Rombusch K. Chem. Ber. 88 (1955) 1334
5. Connors T.A., Mauger A.B., Peutherer M.A., and Ross W.C.J. J. Chem. Soc. (1962) 4601
6. Kaji E., and Zen S. Bull. Chem. Soc. Jpn 46 (1973) 337
7. Fu Y., Hammarstrom L.G., Miller T.J., Franczek F.R., Mc Laughlin M.L., and Hammer R.P. J. Org. Chem. 66 (2001) 7118
8. O'Donnell M.J. Aldrichim. Acta 34 (2001) 3
9. O'Donnell M.J., and Polt R.L. J. Org. Chem. 47 (1982) 2663
10. Allwein S.P., Secord E.A., Martins A., Mitten J.V., Nelson T.D., Kress M.H., and Dolling H. Synlett (2004) 2489
11. O'Donnell M.J., Wu S., and Huffman J.C. Tetrahedron 50 (1994) 4507
12. O'Donnell M.J. Acc. Chem. Res. 37 (2004) 506
13. Kitamura M., Shirakawa S., and Maruoka K. Angew. Chem., Int. Ed. 44 (2005) 1549
14. O'Donnell M.J., Wojciechowski K., Ghosez L., Navarro M., Sainte F., and Antoine J.P. Synthesis 4 (1984) 313
15. Park K.-H., Abbate E., Olmstead M.M., Kurth M.J., and Najdi S. Chem. Commun. 16 (1998) 1679
16. Laue K.W., and Haufe G. Synthesis 10 (1998) 1453
17. 2Et).
18. 2H).
19. Fonze E., Charlier P., To'th Y., Vermeire M., Raquet X., Dubus A., and Frere J.M. Acta Crystallogr., Sect. D: Biol. Crystallogr. D51 (1995) 682
20. Swaren P., Maveyraud L., Raquet X., Cabantous S., Duez C., Pedelacq J.-D., Mariotte-Boyer S., Mourey L., Labia R., Nicolas-Chanoine M.-H., Nordmann P., Frere J.-M., and Samama J.-P. J. Biol. Chem. 273 (1998) 26714
21. Dubus A., Ledent P., Lamotte-Brasseur J., and Frere J.M. Proteins 25 (1996) 473
22. Paetzel M., Danel F., De Castro L., Mosimann S.C., Page M.G.P., and Strynadka N.C.J. Nat. Struct. Biol. 7 (2000) 918
23. Golemi D., Maveyraud L., Vakulenko S., Tranier S., Ishiwata A., Kotra L.P., Samama J.-P., and Mobashery S. J. Am. Chem. Soc. 122 (2000) 6132
24. Carfi A., Duee E., Galleni M., Frere J.-M., and Dideberg O. Acta Crystallogr., Sect. D: Biol. Crystallogr. D54 (1998) 313
25. Llarrull L.I., Tioni M.F., Kowalski J., Bennett B., and Vila A.J. J. Biol. Chem. 282 (2007) 30586
26. I versus inhibitor concentration (ratios of hydrolysis in the absence and in the presence of inhibitors) gave the inhibition constant indicated in Table 2. All experiments were performed three times.
27. Ledent P., Duez C., Vanhove M., Lejeune A., Fonze E., Charlier P., Rhazi-Filali F., Thamm I., Guillaume G., Samyn B., Devreese B., Van Beeumen J., Lamotte-Brasseur J., and Frere J.-M. FEBS Lett. 413 (1997) 194
28. 3,24 Typically, monoclinic crystals were obtained using the hanging drop vapor diffusion method with drops containing 5 μL of a protein solution (at a concentration of 40 mg/mL in 50 mM NaCl, 10 mM Tris buffer, pH 7.2) and 5 μL of 10% PEG 6000 in 100 mM sodium citrate buffer (pH 3.4), equilibrated against 1 mL of the latter solution at 20 °C. The BS3-isocitrate crystals were obtained in the same conditions, by replacing the citrate buffer by a 100 mM sodium isocitrate buffer at the same pH. The BS3-aminocitrate crystals were grown in drops containing 5 μL of a protein solution (at a concentration of 38 mg/mL in 50 mM NaCl, 10 mM Tris buffer, pH 7.2), 4 μL of 8% PEG 6000 in 100 mM sodium aminocitrate buffer (pH 3.4) plus 1 μL of 0.1 M urea additive, equilibrated against 1 mL of a 20% PEG 6000 solution, at 20 °C. X-ray diffraction experiments were carried out under cryogenic conditions (100 K) after transferring the crystals into a reservoir solution supplemented with 50% glycerol. The diffraction data for the BS3-isocitrate crystal were measured at ESRF (Grenoble, France) on the FIP-BM30a beamline (λ = 1.0 Å) using a MarResearch 165 mm CCD detector. Data for the BS3-aminocitrate crystal were collected with a Rigaku RU-200 rotating anode generator operating at 40 kV and 100 mA and a MarResearch Mar345 Imaging Plate (λ = 1.5418 Å). Intensities were indexed and integrated using MOSFLM version 6.01. The scaling of the intensity data was accomplished with SCALA of the CCP4 program suite and all corresponding statistics are available as Supplementary data. The atomic coordinates are available at the Protein Data Bank under the codes 1I2S (citrate), 1W7F (isocitrate) and 3B3X (aminocitrate).
29. Matagne A., Lamotte-Brasseur J., and Frere J.-M. Biochem. J. 330 (1998) 581
30. One diastereoisomer, which configuration is (2R,3S), was found in the enzymic cavity:. Heretsch P., Thomas F., Aurich A., Krautscheid H., Sicker D., and Giannis A. Angew. Chem., Int. Ed. 47 (2008) 1958
31. Besong G.E., Bostock J.M., Stubbings W., Chopra I., Roper D.I., Lloyd A.J., Fishwick C.W.G., and Johnson A.P. Angew. Chem., Int. Ed. 39 (2005) 6403
32. In the class C β-lactamase CMY2 of Klebsiella pneumoniae (β-lactamase structurally close to P99 enzyme), the citrate molecule seems to make a 180° rotation in the active site, in comparison with its position in the BS3 catalytic cleft (see Supplementary data). The atomic coordinates are available at the Protein Data Bank under the code 1ZC2.
33. Brown M.R., Shankar R., and Sallis J.D. J. Labelled. Compd. Radiopharm. 21 (1984) 905
34. Tsao J.W., Schoen F.J., Shankar R., Sallis J.D., and Levy R.J. Biomaterials 9 (1988) 393
35. Shankar R., Crowden S., and Sallis J.D. Atherosclerosis 52 (1984) 191
36. Shankar R., Brown M.R., Wong L.K., and Sallis J.D. Experientia 40 (1984) 265
37. Yamamoto, H.; Koide, S.; Takayanagi, Y. PCT Int. Appl. WO 9635662, 1996.
38. Takahashi, M. Jpn Kokai Tokkyo Koho JP 09059162, 1997.